The goal of this mouse models of human cancer consortium (MMHCC) application is to further develop the mouse as a predictive model in the search for effective human cancer therapies. With the support of the current MMHCC grant, we have developed innovative tools and approaches to modeling human cancer in the mouse and have made both our tools and strategies accessible to the community. In its initial iteration, RNA interference was applied as a genetic tool to study various cancer phenotypes in the mouse. These experiments were remarkably successful, leading to the identification and characterization of tumor suppressor genes, new modes of tumor suppression involving interplay between senescent cancer cells and the host, and the identification of drug modifying genes. They also functionally established roles for microRNAs as oncogenes and key components of tumor suppressor networks. At the same time, technological advances enabled our team to move beyond these initial objectives into new systems and discovery directions, including the development of new mosaic models, RNAi technology, and genomic platforms for characterizing the cancer genome at virtually every level. In this application, we propose to create a roadmap that synthesizes these efforts, using the mouse to filter data emerging from the many human cancer genomics efforts to identify key mediators of tumor development. We will create mouse models based upon emerging human cancer genomics and existing knowledge of cancer-relevant pathways. Using comparative, genome-wide RNAi screens in mouse and human cell lines and mouse tumors, we will assess the power of the genetically matched mouse models to both identify and validate new therapeutic approaches for human cancer. While we will work primarily in a breast cancer model, the path that we pave will be applicable to virtually any tumor type. The foundation of this MMHCC application is the continuing and demonstrably productive collaboration of a group of investigators, who each bring unique skills to the program. In virtually every case, the collaborating labs have developed key technologies and approaches for analyzing the human cancer genome and for translating that information into mouse models. While the current application is certainly built upon the strong foundations created by the previous grant, we have recruited new investigators to reflect the imperative of integrating and exploiting human cancer genetics through strategies that could scarcely have been envisioned at the prior submission. Indeed, our program is designed to complement the efforts of The Cancer Genome Atlas project by providing a blueprint for the functional annotation of the cancer genome.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA105388-09
Application #
8331919
Study Section
Special Emphasis Panel (ZCA1-SRLB-Q (M1))
Program Officer
Marks, Cheryl L
Project Start
2004-04-01
Project End
2014-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
9
Fiscal Year
2012
Total Cost
$907,845
Indirect Cost
$450,003
Name
Cold Spring Harbor Laboratory
Department
Type
DUNS #
065968786
City
Cold Spring Harbor
State
NY
Country
United States
Zip Code
11724
Miething, Cornelius; Scuoppo, Claudio; Bosbach, Benedikt et al. (2014) PTEN action in leukaemia dictated by the tissue microenvironment. Nature 510:402-6
Feigin, Michael E; Akshinthala, S Dipikaa; Araki, Kiyomi et al. (2014) Mislocalization of the cell polarity protein scribble promotes mammary tumorigenesis and is associated with basal breast cancer. Cancer Res 74:3180-94
dos Santos, Camila O; Rebbeck, Clare; Rozhkova, Elena et al. (2013) Molecular hierarchy of mammary differentiation yields refined markers of mammary stem cells. Proc Natl Acad Sci U S A 110:7123-30
Wang, Hui; Lacoche, Sam; Huang, Ling et al. (2013) Rotational motion during three-dimensional morphogenesis of mammary epithelial acini relates to laminin matrix assembly. Proc Natl Acad Sci U S A 110:163-8
Sawey, Eric T; Chanrion, Maia; Cai, Chunlin et al. (2011) Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell 19:347-58
Lucs, A V; Muller, W J; Muthuswamy, S K (2010) Shc is required for ErbB2-induced inhibition of apoptosis but is dispensable for cell proliferation and disruption of cell polarity. Oncogene 29:174-87
Feigin, Michael E; Muthuswamy, Senthil K (2009) Polarity proteins regulate mammalian cell-cell junctions and cancer pathogenesis. Curr Opin Cell Biol 21:694-700
Bric, Anka; Miething, Cornelius; Bialucha, Carl Uli et al. (2009) Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell 16:324-35
Zhan, Lixing; Rosenberg, Avi; Bergami, Kenneth C et al. (2008) Deregulation of scribble promotes mammary tumorigenesis and reveals a role for cell polarity in carcinoma. Cell 135:865-78
Nolan, Marissa E; Aranda, Victoria; Lee, Sangjun et al. (2008) The polarity protein Par6 induces cell proliferation and is overexpressed in breast cancer. Cancer Res 68:8201-9

Showing the most recent 10 out of 14 publications